Skip to main content

Psoriatic arthritis

pso.arm_.JPG

Risankizumab for Active Psoriatic Arthritis

Nov 26, 2021

The arsenal of therapeutics for psoriatic arthritis continues to increase. Risankizumab is an IL-23 inhibitor to the p19 subunit, currently being investigated for treatment of psoriatic arthritis. I’m excited to report about the combined results from two clinical trials on Risankizumab

Read Article
rachel.tate

Safety of Psoriatic Biologics in Pregnancy

Nov 24, 2021

Little is known about the safety of newer biologic use during pregnancy, especially in patients who either conceive while on a biologic or must remain on a biologic during pregnancy (often the case with IBD and inflammatory arthritis). A report from ACR 2021 (Abstract 1713) examined the risk

Read Article
Pipeline

Emerging Therapies in Spondyloarthritis: A Promising Pipeline

Nov 24, 2021

Growing awareness of spondyloarthropathies over the last two decades has led to a better understanding of the pathophysiology of spondyloarthritis, and subsequently increased interest in more distinct, disease state specific treatment options.

Read Article
HAQ.RAPID

RAPID3 in Assessing Psoriatic Arthritis

Nov 18, 2021

My research shows that up to 50% of rheumatologists measure something in the course of their daily assessments, and RAPID3 is most popular, being employed by 31% of rheumatologists.

Read Article
PSA2L.jpg

An Old Friend – Methotrexate in Psoriatic Arthritis

Nov 16, 2021

Methotrexate (MTX) remains one of our most used and reliable tools against a variety of rheumatic diseases, including PsA. When the time comes, as it often does, to escalate from a MTX-monotherapy approach, we have several options. In clinic, initiation of these other medications has often been

Read Article
Best of PSA from Sunday Sessions: Dr. Rachel Tate ( @uptoTate) discusses the RheumNow PSA faculty's best PsA abstracts from Sunday sessions, including abstracts #0750 and #0944, which were presented at the #ACR21 annual meeting.https://t.co/wgMq2rsWNj https://t.co/Z2By90rBEy
Dr. John Cush @RheumNow( View Tweet )
Nov 15, 2021
Lipidomic Differences in PsA and RA: Dr. Pedro Castillo ( @_Castillo_Pedro) discusses abstract #0946 presented at the #ACR21 annual meeting.https://t.co/M8O1OdvFAk https://t.co/4QMgXPhLzn
Dr. John Cush @RheumNow( View Tweet )
Nov 15, 2021
ICYMI: Risankizumab for Active Psoriatic Arthritis with Dr. Robert Chao ( @doctorRBC ) #ACR21https://t.co/jRLem8YWpv https://t.co/5EQB1Y38Xs
Dr. John Cush @RheumNow( View Tweet )
Nov 13, 2021
RheumNow Podcast square

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

Nov 12, 2021

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Read Article
Psoriatic Arthritis: What's with Brepocitinib? Dr. Eric Ruderman ( @JointMD ) discusses abstract #0488 presented at the #ACR21 annual meeting. https://t.co/mq0IMwyMSk https://t.co/oJAJS0DpQz
Dr. John Cush @RheumNow( View Tweet )
Nov 12, 2021
unhappy%20patient.jpg

Psoriatic Arthritis: "What Matters" to Patients, Physicians

A study presented today by Mease et al. addresses the vital gap between what patients and physicians consider disabling because of PsA, and emphasizes “what matters” in a daily clinical encounter while dealing with PsA.

Read Article
ACR Best

ACR21 Best Abstracts - Day 4

Nov 10, 2021

On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these 15 as their favorite reports.

Read Article
Targeting the HUGE dilemma!🎯 #Psoriatic vs Erosive #OA PsA 👉 Fluffy bone formation(enthesitis of phalanges) 👉 Marginal erosions(vs central) 👉 Many jts in same digit(ray inv) 👉 Periarticular SOFT tissue swelling (dactylitis). 👉 NOT much hand OA #ACR21 RadiologyBootCamp https://t.co/OQLPoeRLny
Ashima Makol MD @AshimaMakol( View Tweet )
Nov 09, 2021
Upadacitinib PsA w/axial involvement - post-hoc analysis of SELECT-PsA 1 and S-PsA-2 Statistically greater response in axial dz compared to placebo in both dz dx'ed by investigator alone & on investigator + PRO-based criteriahttps://t.co/YPc5fx9wAR#ACR21 Abst1945 @RheumNow

Pedro Castillo @_Castillo_Pedro( View Tweet )

Nov 09, 2021
Dr. Alexis Ogdie on opioid use in PsA and axSpA, highlighting need for better interventions. 🔹21% of PsA pts (n=828) and 27% of axSpA (n=334) reported prescription opiate use. 🔹⬆️BASDI & HAQ-DI =>⬆️opiate use & costshttps://t.co/Id658ocDVf#ACR21 Abst1777 @RheumNow

Pedro Castillo @_Castillo_Pedro( View Tweet )

Nov 09, 2021
⭐️From 2012 – 2017 NIS data significant 🔽 in sepsis, SSTI, and UTI in patients with PsA despite the increased use of biologics over the years ⭐️No statistical difference pneumonia trend in PsA Abst# 1783 #ACR21 @Rheumnow https://t.co/ToxgRb0acP
swethaann23 @swethaann23( View Tweet )
Nov 09, 2021
Direct-to-Patient (DA) PsA Screening Survey sent to patients with Ps without PsA led to earlier diagnosis of PsA in 0.4%(n=1149 patients) as compared to 0.3%(n=1150) receiving standard of care (SOC). Mean times to PsA diagnosis 66d ▶️ DA 77d ▶️SOC Abst# 1781 #ACR21 @RheumNow https://t.co/qxjPCU0vnI
swethaann23 @swethaann23( View Tweet )
Nov 09, 2021
EULAR19.abstract.jpg (keep)

ACR21 – Day 3 Report

Nov 09, 2021

Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: secukinumab efficacy in juvenile PsA; VEXAS - predicting poor outcomes; and the FDA Safety Update session.

Read Article
switch.jpg

Monitoring Infliximab Drug Levels Improves Efficacy

Nov 09, 2021

Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions?



The NOR-DRUM trials (A and B) are the first randomized trials to assess the impact of proactive therapeutic drug monitoring of infliximab in the treatment of

Read Article
Hospitalisation for heart failure ⬆️ in inflammatory diseases. RA>PsA>AS>PsO . HRs 1.1-1.6 compared to general population. Abstr#1925 #ACR21 @RheumNow https://t.co/kKlGQM5Tcg
Richard Conway @RichardPAConway( View Tweet )
Nov 09, 2021
Why is there more CHF in #RheumatoidArthritis ? Also dose response between highest inflammation RA the PsA then axSpA then PsO. ?Cytokine profile varying with disease and maybe CRP. Who knows. Abst#1925 #ACR21 @RheumNow https://t.co/JIH3qwkLpx
Nov 09, 2021
Should we be measuring drug levels in pts taking infliximab? ⭐️Drug monitoring vs. standard dosing showed 73% sustained control vs. 55% (RA, PsA, SpA, UC, Crohn's, PsO) #ACR21 Abs#1946 #ACRBest @RheumNow https://t.co/sWMen50ljP https://t.co/F4Wpqis3id
Robert B Chao, MD @doctorRBC( View Tweet )
Nov 09, 2021
Prospective study of PsO screened @ derm clinics 🔹PsO➕>3 mo back pain starting <45yo➕no biologics➡️rheum ref, 100 pts seen➡️19 dx'ed as: 🔹14 axPsA, 68% met axSpA ASAS, 11/14 w/o pPsA 🔹5 pPsA w/o axial dzhttps://t.co/azoks5CHCP#ACR21 Abst#1796 @RheumNow

Pedro Castillo @_Castillo_Pedro( View Tweet )

Nov 09, 2021
Elevated CRP levels (>3) in PsA associated with ⬆️risk of cardiovascular events ⭐️NSAID use significantly REDUCED risk of CV events Abs#1920 #ACR21 @RheumNow https://t.co/gIz9f4SlWo https://t.co/V4uDeO3Iuz
Robert B Chao, MD @doctorRBC( View Tweet )
Nov 09, 2021
Racial differences in PsA patients in large US real world database 95% Whites (W) and 5% were AA NSAIDs: 80% W and 78% AAs TNFI: 51% W and 41% of AAs DMARDs: 72% of W and 98% of AAs HTN/DM/Obesity/Gout 🔼 AA Cancer/osteoporosis /anxiety 🔼 whites Abst#1780 #ACR21 @Rheumnow https://t.co/7ee4bVU7ZA
swethaann23 @swethaann23( View Tweet )
Nov 09, 2021
×